VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership

Questions around this news

What cell line development partnership did VERAXA announce?
VERAXA selected ATUM to develop stable clonal cell lines for its lead BiTAC T-cell engager candidate. The release says ATUM will use its Leap-In Transposase technology. The work is intended to support manufacturing and analytical development, as well as nonclinical studies, while the candidate moves toward IND/CTA-enabling studies.
How does cell line development fit into preparing a drug candidate for clinical testing?
Cell line development helps establish cells that can produce a biological drug consistently. In the release, this work is part of preparing the lead candidate for manufacturing and analytical development, alongside nonclinical studies. These activities are described as steps toward IND/CTA-enabling studies, which take place before clinical testing.
What is a T-cell engager?
A T-cell engager is a type of therapeutic molecule designed to bring a T cell, an immune cell, into contact with a target cell. Some are designed to direct T cells toward cancer cells. The release describes VERAXA’s platform as aiming to improve selectivity and potentially reduce toxicity associated with conventional approaches.
What are IND/CTA-enabling studies?
IND/CTA-enabling studies are preclinical activities used to assemble evidence for a regulatory submission before human testing. IND refers to an Investigational New Drug application in the United States; CTA refers to a Clinical Trial Application used in other jurisdictions. The work may include nonclinical safety studies and information about how a candidate will be manufactured.

The company has initiated cell line development for its lead BiTAC(R) T-cell engager program, selecting ATUM to support manufacturing development as the candidate advances toward IND/CTA-enabling studies.
ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA’s lead therapeutic candidate.
The collaboration represents an important development milestone, supporting manufacturing, analytical development and nonclinical studies required before clinical testing.
VERAXA’s BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches.
The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC(R) T-cell engager (“BiTAC(R)-TCE”) program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development.

The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase(R) technology. According to VERAXA, the collaboration is intended to…

At a glance

Company: VERAXA Biotech
Ticker: NASDAQ: VRXA
Announcement: Partnership

Products and programs

BiTAC T-cell engager program
Leap-In Transposase technology

SEC filings

Earlier from VERAXA Biotech

Back to News Center

VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership

Questions around this news

What cell line development partnership did VERAXA announce?

How does cell line development fit into preparing a drug candidate for clinical testing?

What is a T-cell engager?

What are IND/CTA-enabling studies?

At a glance

Products and programs

SEC filings

Earlier from VERAXA Biotech